Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.
Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, Limiti S, Colafigli M, Tamburrini E, Cauda R, De Luca A, Di Giambenedetto S. Ciccarelli N, et al. Among authors: grima p. Antivir Ther. 2015;20(4):433-40. doi: 10.3851/IMP2925. Epub 2014 Dec 11. Antivir Ther. 2015. PMID: 25504667
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group. Di Giambenedetto S, et al. Among authors: grima p. J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557. J Antimicrob Chemother. 2017. PMID: 28093483 Clinical Trial.
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group. Fabbiani M, et al. Among authors: grima p. J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123. J Antimicrob Chemother. 2018. PMID: 29668978 Clinical Trial.
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.
Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M, D'Avino A, Mondi A, Borghetti A, Fantoni M, Cauda R, Di Giambenedetto S. Fabbiani M, et al. Among authors: grima p. BMC Infect Dis. 2014 Jan 13;14:26. doi: 10.1186/1471-2334-14-26. BMC Infect Dis. 2014. PMID: 24418191 Free PMC article.
74 results